Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets $500M annual cost savings, aiming to boost operating margins above 23% by 2028.

Seeking Alpha • Dec 12, 2025

These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?

New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.

The Motley Fool • Dec 5, 2025

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity

Three stocks that are performing well in 2025 just made notable buyback announcements. All three have achieved returns north of 20% this year, beating the 18% return of the S&P 500 Index.

MarketBeat • Dec 1, 2025

Solventum to Participate in the 2025 Piper Sandler Healthcare Conference

ST. PAUL, Minn. , Nov. 25, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2, 2025, beginning at approximately 10:00 a.m.

PRNewsWire • Nov 25, 2025

Solventum Announces Agreement to Acquire Acera Surgical

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million market segment in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

PRNewsWire • Nov 20, 2025

Solventum Announces $1 Billion Share Repurchase Program

ST. PAUL, Minn. , Nov. 20, 2025 /PRNewswire/ -- Solventum  (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.

PRNewsWire • Nov 20, 2025

Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript

Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.

Seeking Alpha • Nov 12, 2025

SOLV vs. DHR: Which Stock Is the Better Value Option?

Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Nov 12, 2025

Solventum (SOLV) Upgraded to Strong Buy: What Does It Mean for the Stock?

Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Nov 11, 2025